NCT01861197Unknown2 期
Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 27
- 试验地点
- 1
- 主要终点
- response rate
研究概览
简要总结
Efficacy of Dovitinib for Squamous NSCLC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •histologically confirmed squamous NSCLC
- •Previously treated with one or two lines of chemotherapy
- •FGFR amplification (FISH > 5 copies of genes)
- •20 years or older
- •ECOG PS 0-2
排除标准
- •active infection
- •uncontrolled brain metastasis
- •unstable angina or MI
研究组 & 干预措施
Dovitinib monotherapy
Experimental
干预措施: Dovitinib (Drug)
结局指标
主要结局
response rate
时间窗: 6 months
次要结局
未报告次要终点
研究者
Myung-Ju Ahn
Professor
Samsung Medical Center
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Central Nervous System(CNS) Efficacy of DacomitinibNon Small Cell Lung CancerBrain MetastasesNCT04675008Samsung Medical Center30
已完成
2 期
Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line ChemotherapySquamous Cell Carcinoma of BronchusNCT01485809Seoul Veterans Hospital36
Unknown
2 期
EGFR Mutation Positive NSCLC Patients With Gefitinib and ThalidomideNSCLC Stage IVChemotherapy EffectNCT03341494Fujian Cancer Hospital128
Unknown
2 期
First Line Gefitinib by FDG-PET Metabolic ResponseNon-small Cell Lung CancerNCT01510990Asan Medical Center60
终止
2 期
FGFR Inhibitor in FGFR Dysregulated CancerLung CancerPulmonary NeoplasmSquamous Cell Lung CancerNSCLC Stage IVNSCLCNCT03827850Lung Cancer Group Cologne22